BPC-157 Dosage Calculator

BPC-157, an acronym for Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of the human gastric juice protein BPC. It is sometimes also referenced in the literature under the development designation PL 14736. BPC-157 does not appear as a natural peptide in the body at the concentrations studied in animal models, but the parent gastric protein from which it derives is thought to play a cytoprotective role in gastrointestinal tissue, a discovery that prompted the initial isolation and synthesis of the fragment.

Research into BPC-157 has accumulated primarily through rodent and in vitro studies since the 1990s, with work largely originating from the group of Dr. Predrag Sikiric at the University of Zagreb. Published research has investigated effects on tendon, ligament, muscle, and bone healing; gastrointestinal ulcer repair; neurological regeneration; cardiovascular modulation; and systemic inflammatory pathways. Notably, BPC-157 appears to upregulate the VEGFR2 (vascular endothelial growth factor receptor 2) pathway and promote angiogenesis, which may be central to its reported accelerative healing effects in animal injury models.

BPC-157 exerts its biological effects through multiple intracellular pathways rather than a single receptor target. Among the most studied mechanisms is its activation of the VEGFR2 (KDR) receptor pathway, which drives angiogenesis — the formation of new blood vessels — at injury sites, accelerating the delivery of nutrients and growth factors needed for tissue repair. In tendon fibroblast studies, BPC-157 has been shown to stimulate the outgrowth of tendon cells in culture and increase expression of growth hormone receptor, suggesting a potential interaction with the GH/IGF-1 axis.

BPC-157 also modulates the nitric oxide (NO) system, exhibiting both NO-generating and NO-inhibiting effects depending on the experimental context, which may contribute to its gastroprotective and systemic cytoprotective properties. In the central nervous system, it has been shown to influence dopaminergic and serotonergic systems in rodent models, producing behavioral effects in models of depression and addictive behavior. An absence of systemic toxicity in rodent studies, even at very high doses, is consistently reported in the primary literature.

BPC-157 lyophilized powder is reconstituted with bacteriostatic water for injection. For a standard 5 mg research vial, inject 2 mL of bacteriostatic water slowly against the glass wall of the vial. Allow the solution to rest for 60 seconds, then swirl gently until the powder dissolves — BPC-157 is a small, water-soluble peptide and typically dissolves readily without prolonged mixing. Do not shake the vial vigorously, as this can cause bubbling and potential peptide degradation.

A 5 mg vial with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL (2.5 mcg per microliter). A common 250 mcg dose requires 0.10 mL (10 IU on a U100 insulin syringe), making dose measurement straightforward and precise. Administer subcutaneously, ideally near the injury site when targeting musculoskeletal injuries, or in the abdomen for systemic effects.

BPC-157 animal research studies have used a wide range of doses, most commonly in the range of 1–10 mcg/kg body weight for subcutaneous or intraperitoneal administration. Scaling these preclinical doses to human-equivalent doses using standard body surface area conversion factors (Km factor of 37 for human) suggests an approximate human-equivalent dose in the range of 100–500 mcg per day for a 70 kg subject, which aligns with the most commonly discussed dose ranges in the research community.

The most frequently referenced doses in the research community for subcutaneous administration are 250–500 mcg per day, typically administered once daily or split into two doses. Some protocols continue daily administration for 4–6 weeks for acute injury research, while maintenance-style low-dose protocols (200–250 mcg) are sometimes extended for longer periods in gastrointestinal research contexts.

Note: BPC-157 is also available in an oral or sublingual capsule form (arginate salt stabilized), which bypasses reconstitution requirements and may be preferentially studied for gastrointestinal-targeted research. For systemic or localized injectable research, the lyophilized powder form requires reconstitution as described.

Lyophilized BPC-157 powder is relatively stable at room temperature for short periods but should be stored at 2–8°C for research timelines extending beyond a few weeks, and at -20°C for long-term storage (six months or more). Once reconstituted in bacteriostatic water, store at 2–8°C and use within 28 days for optimal activity. Reconstituted BPC-157 is less stable than the dry powder; some degradation at room temperature occurs relatively quickly compared to larger peptides. Keep vials away from light and heat sources, and avoid repeated freeze-thaw cycles of the reconstituted solution.

BPC-157 has demonstrated a remarkably clean safety profile in rodent studies, with no observed toxicity reported in studies using doses far exceeding those typically used in research protocols. No lethal dose (LD50) has been established in mice even at high doses. This profile is consistent across multiple independent research groups. Human data is extremely limited, as no completed, published Phase 2 or Phase 3 human clinical trials have been reported in the primary literature. The peptide remains a research chemical without established safety data in humans. Preliminary Phase 1 trial work for a topical BPC-157 formulation (PL 14736) in inflammatory bowel disease was conducted but full trial results were not broadly published. Treat all research use as exploratory.